Clinical trials: Visceral Fat
Obesity, Intra-Abdominal Fat
Effect of a Probiotic on Visceral Fat Accumulation
The study's main objective is to investigate if an extract containing the probiotic Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145) has a positive effect on the accumulation of abdominal visceral fat in people with…
- Conditions
- Obesity, Intra-Abdominal Fat, Subcutaneous Fat, Abdominal
- Trial name
- BIFFAT (NCT02921217)
- Testing
- Active Probiotic, Inactivated probiotic, Control
- Where
- Spain
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Biopolis S.L.
Metabolic Syndrome
VIsceral Fat Reduction Assessed by CT-scan On RImonabAnt
Primary objective: To assess the effect of rimonabant on visceral fat area over a period of 12 months when prescribed with a mild hypocaloric diet in abdominally obese patients with metabolic syndrome Secondary objectives: To…
- Trial name
- VICTORIA (NCT00299325)
- Testing
- Rimonabant, Mild hypocaloric diet
- Where
- 9 sites in United States, Canada and 7 more
- Volunteers
- 254 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2, Insulin Resistance
Evaluation of Intra-Abdominal Fat Extraction Using HydraSolve T2D™ in Obese Subjects With Type 2 Diabetes
This study will investigate the safety and efficacy of the investigational use of the HydraSolve T2D™ System in improving blood glucose control and insulin resistance in patients with obesity (Class 1, BMI 30-39.9 kg/m2) and type…
- Trial name
- NCT03953963
- Testing
- HydraSolve T2D™
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Medality Medical
Focus: Understanding the Obesogenic Potential of Sugars and Non-caloric Sweeteners
The Effect of Sugar Sweetened and Diet Beverages Consumed as Part of a Weight-Maintenance Diet on Fat Storage
The purpose of this study is to investigate the effects of consumption of sugar sweetened and diet beverages on overall fat mass and the fat mass of various tissues implicated in the dysregulation of glucose metabolism.
- Trial name
- NCT02252952
- Testing
- Beverage Consumption
- Where
- United States
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Rippe Lifestyle Institute
Metabolic Syndrome
Efficacy of STABLOR® on Visceral Fat Mass Reduction in Patients With Metabolic Syndrome
The primary objective of the study is to assess the efficacy of STABLOR® consumption on visceral fat mass compared to placebo, in persons with metabolic syndrome during 12 weeks of consumption.
- Trial name
- OBEMINALE2 (NCT03692806)
- Testing
- Stablor
- Where
- 6 sites in France, Ireland
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- LNC THERAPEUTICS
HIV, HIV-Infections
The Visceral Adiposity Measurement and Observation Study
The Visceral Adiposity Measurement and Observation Study
- Conditions
- HIV, HIV-Infections, HIV-1-infection, HIV I Infection
- Trial name
- VAMOS (NCT05383456)
- Testing
- Diagnostic Test, HIV Anti-retroviral Background Therapy
- Where
- 8 sites in United States
- Volunteers
- 196 people
- Sponsor
- Theratechnologies
Obesity
Technical Validation of Lunar iDXA Visceral Fat Tool
The goal of this project is to compare visceral fat measurements derived from Lunar iDXA total body scans and from Computed Tomography (CT) scans of the abdominal region for a Chinese population.
- Trial name
- NCT01110161
- Testing
- Visceral fat mass measurement
- Where
- China
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Obesity, Overweight
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight
The main purpose of this study is to see how orforglipron affects the amount of body fat compared with placebo in participants with obesity or overweight. Participation in the study will last approximately 8 months.
- Trial name
- NCT06824051
- Testing
- Orforglipron
- Where
- 4 sites in United States
- Volunteers
- 120 people
- Sponsor
- Eli Lilly and Company
Obesity
A Study of Safety and Efficacy of Topiramate in Male Patients With Abdominal Obesity
The purposes of this study are to compare the effects of Topiramate and placebo on abdominal visceral fat accumulation at 6 months and to evaluate the safety of Topiramate for up to 12 months of continued treatment in male…
- Trial name
- NCT00231608
- Testing
- topiramate
- Volunteers
- 68 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Abdominal Obesity, Type 2 Diabetes
ORAL ANTIDIABETICS EFFECT ON VISCERAL FAT
Weight control is an essential part of treatment for type 2 diabetes (T2D) patients. Weight loss is associated with decreased haemoglobin A1c (A1c) levels.
- Trial name
- NCT05032001
- Testing
- Biguanide, DPP4 inhibitors, SGLT2 inhibitors
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- Metabolic Research Unit
Obesity, Visceral, Obesity; Endocrine
Study of Lipolysis of Visceral Reserve Fat Using Tecar Therapy.
The Scope of this study is to assess the visceral and subcutaneous fat loss in patients having Tecar (Radiofrequency) Therapy and its effects on other anthropometric variables, adipokines and inflammation.
- Trial name
- NCT06377358
- Testing
- Tecar Therapy
- Where
- Spain
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- CAPENERGY MEDICAL, SL
Obesity
Comparison of Medifast's 5 & 1 Plan to a Food-based Plan of Equal Calories
Portion-controlled meal replacements have been shown to be an effective weight control strategy in overweight and obese individuals.
- Trial name
- NCT01011491
- Testing
- Medifast 5 & 1 Plan for weight loss and weight maintenance, Food-based diet plan for weight loss and weight maintenance
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Medifast, Inc.
Obesity
Technical Validation of Lunar iDXA (GE Healthcare) Visceral Fat Tool
The goal of this project is to compare visceral fat measurements derived from Lunar iDXA total body scans and from Computed Tomography (CT) scans of the abdominal region.
- Trial name
- NCT00987298
- Testing
- Visceral fat mass measurement
- Where
- United States
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Metabolic Syndrome
Effect of Stablor on Visceral Fat Loss in Patients With a Metabolic Syndrome
The purpose of the study is to evaluate the impact of the intake of a dietary supplement STABLOR™ on the change of the abdominal visceral fat mass in patients with a metabolic syndrome.
- Trial name
- NCT01755104
- Testing
- Stablor
- Where
- 2 sites in Canada, France
- Volunteers
- 118 people
- Sponsor
- Laboratoires Nutrition et Cardiometabolisme
Type 2 Diabetes, Metabolic Syndrome
Clinical Study on the Effect of a Synbiotic on Body Fat Mass
In this trial the effect of a synbiotic consisting of the three different strains of Lactobacillus fermentum and acacia gum (gum arabic) on body fat mass, body weight, long-term glycemia, insulin resistance and other risk factors…
- Conditions
- Type 2 Diabetes, Metabolic Syndrome, Obesity, Abdominal, Obesity, Visceral
- Trial name
- NCT04754464
- Testing
- synbiotic, microcrystalline cellulose
- Where
- 2 sites in Austria, Germany
- Volunteers
- 120 people
- Sponsor
- Slimbiotics GmbH
Obesity
Study of Efficacy of a Probiotic and Postbiotic in Overweight and Obese Individuals
The study's main objective is to investigate the effect of a probiotic (live bacteria), postbiotic (heat-treated bacteria) on obesity parameters.
- Trial name
- Obelix (NCT05440630)
- Testing
- Probiotics, Postbiotic
- Where
- Mexico
- Volunteers
- healthy volunteers welcome
- Sponsor
- The Archer-Daniels-Midland Company